Parés, Albert

Randomized trial comparing monthly ibandronate and weekly alendronate for osteoporosis in patients with primary biliary cirrhosis: HEPATOLOGY, Vol. 00, No. X, 2013 GUAÑABENS ET AL.

Guañabens, N., Monegal, A., Cerdá, D., Muxí, Á., Gifre, L., Peris, P., & Parés, A. (2013) · Hepatology

Bone health and osteoporosis researchLiver Diseases and Immunity

Cited by 99

Changing nomenclature for PBC: from ‘cirrhosis’ to ‘cholangitis’

Beuers, U., Gershwin, M. E., Gish, R. G., Invernizzi, P., Jones, D. E. J., Lindor, K., Ma, X., Mackay, I. R., Parés, A., Tanaka, A., et al. (2015) · Journal of Hepatology

Liver Diseases and ImmunityPediatric Hepatobiliary Diseases and Treatments

Cited by 97

Autoantibodies against nuclear envelope-associated proteins in primary biliary cirrhosis

Lozano, F., Parés, A., Borche, L., Plana, M., Gallart, T., Rodés, J., & Vives, J. (1988) · Hepatology

Liver Diseases and ImmunityPediatric Hepatobiliary Diseases and Treatments

Cited by 94

Natural history of primary biliary cirrhosis

Parés, A., & Rodés, J. (2003) · Clinics in Liver Disease

Liver Diseases and ImmunityLiver Disease and Transplantation

Cited by 89

Effects of bilirubin and sera from jaundiced patients on osteoblasts: Contribution to the development of osteoporosis in liver diseases

Ruiz-Gaspà, S., Martinez-Ferrer, A., Guañabens, N., Dubreuil, M., Peris, P., Enjuanes, A., de Osaba, M. J. M., Alvarez, L., Monegal, A., Combalia, A., et al. (2010) · Hepatology

Bone Metabolism and DiseasesBone health and osteoporosis research

Cited by 75

Liver and bone

Guañabens, N., & Parés, A. (2010) · Archives of Biochemistry and Biophysics

Bone health and osteoporosis researchBone Metabolism and Diseases

Cited by 71

Sodium fluoride prevents bone loss in primary biliary cirrhosis

Guañabens, N., Parés, A., del Rio, L., Roca, M., Gómez, R., Muñoz, J., & Rodés, J. (1992) · Journal of Hepatology

Bone health and osteoporosis researchLiver Diseases and Immunity

Cited by 68

Osteoporosis in primary biliary cirrhosis: pathogenesis and treatment

Parés, A., & Guañabens, N. (2008) · Clinics in Liver Disease

Bone health and osteoporosis researchLiver Diseases and Immunity

Cited by 63

Management of osteoporosis in liver disease

Guañabens, N., & Parés, A. (2011) · Clinics and Research in Hepatology and Gastroenterology

Bone health and osteoporosis researchBone health and treatments

Cited by 56

Treatment of bone disorders in liver disease

Parés, A., & Guañabens, N. (2006) · Journal of Hepatology

Bone health and osteoporosis researchLiver Disease and Transplantation

Cited by 50

Changing nomenclature for PBC: From 'cirrhosis' to 'cholangitis'

Beuers, U., Gershwin, M. E., Gish, R. G., Invernizzi, P., Jones, D. E. J., Lindor, K., Ma, X., Mackay, I. R., Parés, A., Tanaka, A., et al. (2015) · Clinics and Research in Hepatology and Gastroenterology

Liver Diseases and ImmunityPediatric Hepatobiliary Diseases and Treatments

Cited by 43

Optimizing therapy in primary biliary cholangitis: Alkaline phosphatase at six months identifies one‐year non‐responders and predicts survival

Murillo Perez, C. F., Ioannou, S., Hassanally, I., Trivedi, P. J., Corpechot, C., van der Meer, A. J., Lammers, W. J., Battezzati, P. M., Lindor, K. D., Nevens, F., et al. (2023) · Liver International

Liver Diseases and ImmunityPediatric Hepatobiliary Diseases and Treatments

Cited by 39

Obeticholic acid is associated with improvements in AST-to-platelet ratio index and GLOBE score in patients with primary biliary cholangitis

Harms, M. H., Hirschfield, G. M., Floreani, A., Mayo, M. J., Parés, A., Liberman, A., Malecha, E. S., Pencek, R., MacConell, L., & Hansen, B. E. (2021) · JHEP Reports

Liver Diseases and ImmunityPediatric Hepatobiliary Diseases and Treatments

Cited by 17